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Abstract  
Objectives: To 1) characterise older patients taking warfarin, 2) assess these patients’ level of warfarin knowledge, and 3) describe 
their strengths and limitations in health literacy, and 4) explore relationships between participants’ characteristics, warfarin knowledge 
and health literacy. 
Methods: A warfarin knowledge questionnaire and Health Literacy Questionnaire (HLQ) were administered to older patients (aged >65 
years, N=34) taking warfarin in an Australian general practice setting. 
Results: Key gaps in participant knowledge pertained to the consequences of an international normalized ratio (INR) being below the 
target INR range and safety issues such as when to seek medical attention. A limitation for participants with a lower level of health 
literacy was the ability to appraise health information. Patients who needed assistance in completing the HLQs had significantly lower 
warfarin knowledge scores (p=0.03). Overseas-born participants and those taking 5 or more long-term medications had lower HLQ 
scores for specific scales (p<0.05). 
Conclusion: In this study warfarin knowledge gaps and a limitation of health literacy amongst a small sample of older patients were 
identified. The findings suggest that education and resources may need to be tailored to the needs of older patients taking warfarin 
and their carers to address these knowledge gaps and limitations in health literacy. Patients who may need greater support include 
those that need assistance in completing the HLQ, are overseas-born, or are taking 5 or more long-term medications. 
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INTRODUCTION 
As the use of oral anticoagulants continues to rise, more 
attention is being paid to how well patients are being 
supported in their management of these treatment 
regimens. This is particularly the case in older persons who 
are high users of these medications for long-term 
indications, including stroke prevention in atrial 
fibrillation.1,2 Older people are vulnerable to experiencing 
harm from so-called ‘high alert’ medicines, such as warfarin 
(traditional anticoagulant).3 Therefore, patient education 
regarding adverse effects (i.e., bleeding), dietary Vitamin K 
consumption, potential drug interactions, need for regular 
monitoring, and actions around missed doses, is 
paramount4 especially during transitions of care between 
hospital and primary care settings.5 Despite the advent of 
direct oral anticoagulants (DOACs), warfarin and warfarin 
education may still be needed in certain patient 
populations who are not good candidates for DOACs, such 
as those patients who have: mechanical heart valves6; a 
creatinine clearance of <30mL/minute (calculated by the 
Cockcroft-Gault equation) ; haemodialysis7; other specific 
contraindications; and/or who cannot afford the relatively 
higher costs of the newer agents (depending on the 
medication subsidies available in each country).8 
 
The education of older persons regarding warfarin has, 
however, been suboptimal, contributing to poor 
therapeutic outcomes, such as sub- or supra-therapeutic 
INRs, adverse events (e.g., bleeds), or an increase in 
hospitalisations.9 Educational challenges are more 
pronounced in older patients due to changing cognition, 
function, and psychological wellbeing, as well as lower 
health literacy.10,11  Regarding the latter, the World Health 
Organisation (WHO) defines health literacy as `the 
cognitive and social skills which determine the motivation 
and ability of individuals to gain access to, understand and 
use information in ways which promote and maintain good 
health' and ‘implies the achievement of a level of 
knowledge, personal skills and confidence to take action to 
improve personal and community health by changing 
personal lifestyles and living conditions’.12 In Australia, 
almost 60% of adults (15 to 74 years) have low health 
literacy13, and it has been shown that older age is 
associated with lower health literacy scores.14  
Health literacy has been recognized as a multi-dimensional 
concept and newer tools are now available to measure 
health literacy across several different domains.15 In 
patients taking warfarin, low health literacy has been 
associated with deficits in warfarin knowledge.16 
Recognition of this is critical to developing effective 
educational interventions or resources to better support 
patients taking oral anticoagulants. To our knowledge in 
Australia, there have been no studies that have assessed 
both warfarin knowledge and the health literacy of older 
persons who are taking oral anticoagulants in a primary 
care setting. This is important given the increasing use of 
anticoagulation, and that warfarin therapy remains a 
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primary therapy, despite the increasing availability of 
alternative agents. 
Therefore, the objectives of this descriptive pilot study 
were to: (1) report the characteristics of older patients 
taking warfarin in the local Australian primary care setting; 
2) assess these patients’ level of knowledge about warfarin; 
3) describe their strengths and limitations in health literacy, 
and 4) explore relationships between participants’ 




A descriptive, questionnaire-based pilot study was 
conducted in an Australian general practice (primary care) 
setting between September 2015 and January 2016. 
Approval to conduct this study was granted by the Human 
Research Ethics Committee of the University of Technology 
of Sydney (Project number: 201 4000 863).  
Setting 
A general practice medical centre in The Hills Shire (Greater 
Western Sydney, New South Wales, Australia) was the 
primary location for this study due to its ageing 
population17 and therefore the high prevalence of warfarin 
users being treated for atrial fibrillation.  
Participants and recruitment 
The study participants comprised older patients who were: 
• ≥ 65 years of age 
• taking warfarin therapy for a long-term indication 
(regardless of when the medication was initiated) 
• cognitively intact (based on the clinician’s confirmed 
assessment and knowledge of the patient during the 
screening process) 
• able to communicate in English 
• able to provide informed consent 
For patients who were unable to fulfill the last three 
inclusion criteria, the primary carer who was responsible 
for managing their warfarin therapy was invited to 
participate instead. The carer was asked to complete the 
surveys based on their own knowledge and health literacy. 
To recruit participants, the medical centre staff (5 general 
practitioners, and one on-site cardiologist) screened their 
electronic patient records to identify 87 potential 
participants (80 patients and 7 carers) that met study 
criteria. 36 participants agreed to participate in the study, 
however, 2 participants dropped out during the study due 
to a lack of time to complete the questionnaires and 
provide feedback. Fifty one participants declined to 
participate in the study. The target sample size was based 
on an estimate of the proportion of participants likely to 
attain correct answers to the brief warfarin knowledge 
questionnaire. Using a point-estimate of effect of 65% 
(proportion of patients likely to get at least half the 
answers correct18, with 90% confidence and 10% precision, 
the target sample size was 34 participants.  
A medical receptionist then sent (via postal mail) each 
patient a generic letter informing them about the study and 
inviting them to contact the main researcher (AY). Non-
responders received a once-only telephone call from the 
medical centre to follow up on the invitation (one week 
post first mail out). On contacting the researcher, the 
person’s eligibility (per inclusion criteria) was confirmed 
and consent to participate in the study was obtained. 
Data collection   
Data collection occurred during scheduled face-to-face 
appointments with the researcher at the medical centre, or 
via the telephone. A set of questionnaires was used: 
• purpose-designed questionnaire to record participants’ 
medical history, medication history, history of warfarin use, 
previous education received about warfarin  
• customised brief Warfarin Knowledge Questionnaire  
• Health Literacy Questionnaire (HLQ).19 
Warfarin Knowledge Questionnaire 
To assess participants’ knowledge about basic aspects of 
warfarin therapy, a brief customised 10-item questionnaire 
was developed. The questionnaire comprised a selection of 
open-ended and closed-ended questions (e.g., multiple 
choice answer-style questions), comprising nine questions 
used in previous studies20-22 and one additional question 
(question 8) designed by the authors (online Appendix). 
This shorter customised questionnaire was used instead of 
others (e.g., Oral Anticoagulation Knowledge test (OAK), 
Anticoagulation Knowledge Assessment (AKA), 
Anticoagulation Knowledge Test (AKT)) to enable time-
efficient knowledge assessment via a researcher-
administered questionnaire, and to allow open-ended 
responses in this target older patient population.20,23,24 The 
responses provided to the open-ended questions were 
categorised thematically and coded to enable quantitative 
analysis of data. Responses to all questions were given a 
score of 1 for a correct answer being given; each question 
had equal weighting. The participant’s overall level of basic 
warfarin knowledge was reported as a total score out of 
ten, where a score 5 or greater out of 10 was considered as 
high or good knowledge. A score less than 5 out of 10 was 
considered as low or poor knowledge, as adapted from a 
previous study.25 
Within this descriptive study, no further validation of the 
shortened questionnaire was undertaken beyond checking 
of face validity and pilot-testing among the researchers. 
Health Literacy Questionnaire (HLQ) 
The HLQ was chosen to determine health literacy after 
consideration of other studied health literacy measures 
such as the Newest Vital Sign26, shortened version of the 
Test of Functional Health Literacy in Adults (S-TOFHLA)26, 
shortened version of the Test of Functional Health Literacy 
in Adults (S-TOFHLA)
27
, Rapid Estimate of Adult Literacy in 
Medicine- Short Form (REALM-SF)28 and the Short 
Assessment of Health Literacy-English (SAHL-E).29 The latter 
tools only focus on reading ability, comprehension and 
numeracy, and some also have substantive psychometric 
weaknesses, drawing different conclusions when applied 
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concurrently, and providing limited guidance on how to 
improve health literacy.14,19 
The HLQ uses a multidimensional health literacy profile 
which provides better insight into the health literacy 
strengths and limitations of both individuals and 
populations.19 This tool may better reflect the overall 
health literacy of an individual, as it captures the broad 
components that contribute to it30 and key elements from 
the perspective of the general population, practitioners and 
policymakers.19 The HLQ scales have strong to very strong 
psychometric properties and provide unique insights across 
nine independent indicators of health literacy.19 The HLQ 
comprises of 44 questions which can be administered 
quickly (reported average of 7 to 30 minutes) in 14 
different languages.31  
The validated HLQ measures health literacy and comprises 
44 items spread across 9 scales.15 For each item, 
participants were asked to respond as follows (Table 3):  
• for scales 1 to 5: Strongly Disagree=1, Disagree=2, 
Agree=3, Strongly agree=4.   
• for scales 6 to 9:  Cannot do =1, Very Difficult=2, 
Quite Difficult =3, Quite Easy =4, Very easy =5. 
To determine the overall scale scores, item scores were 
added and the sum divided by the number of items in that 
specific scale.15 Using these scale scores, participants with a 
lower level of health literacy for a particular scale were 
defined as those having a: 
• mean scale score of <3 for scales 1 to 5. That is, they 
on average “strongly disagree” or “disagree” with 
the item statement 
OR 
• mean scale score of < 4 for scales 6 to 9. That is, they 
on average “cannot do” or find it “very difficult” or 
“quite difficult” to do those tasks listed in the item 
statements. 
Conversely, participants with a higher level of health 
literacy for a particular scale were defined as having a: 
• mean scale score of 3 or more for scales 1 to 5. That 
is, they on average “strongly agree” or “agree” with 
the item statements 
OR 
• mean scale score of ≥4 for scales 6 to 9. That is, they 
on average found it “quite easy” or “very easy” to do 
the tasks listed in the item statements. 
Data Analysis 
Quantitative data were analysed using the software 
program IBM SPSS version 23.0 (SPSS Inc., Chicago, II, USA), 
and Microsoft Excel.  Descriptive statistics, such as 
measures of central tendency (e.g., means, medians), were 
used to summarise the characteristics of the participants 
and responses to survey questions. Categorical variables 
were expressed as frequencies and percentages, and 
continuous variables were presented as medians 
(interquartile range). Inferential statistics (non-parametric 
tests, e.g., chi-square test, Mann-Whitney U test, Spearman 
correlation test) were used to explore differences in 
characteristics and responses between patient sub-groups, 
and to explore the relationship between warfarin 
knowledge and health literacy. A significant difference was 
defined as p<0.05.  The categorisation of HLQ scores into 
lower and higher literacy does not rely on an assumption of 
normality in the data, and hence mean cut-off scores were 
used to categorise data. 
 
Table 1. Characteristics of participants (N=34) 
Participant characteristics 
Patients (n=30) 
(% in subgroup) 
Carers (n=4) 
(% in subgroup) 
Warfarin knowledge score (N=34) 
p-value* 
Mean (SD) Median (IQR) 
Median age (years), IQR 81.0, 11.0 61.0, 35.5 N/A N/A N/A 
Age range (years) 67.0 to 99.0 43.0 to 85.0 N/A N/A N/A 
Age Group (years)     P =0.37 
<80 years 12 (40.0) 3 (75.0) 8.3 (1.8) 9.0 (0.8)  
80 years 18 (60.0) 1 (25.0) 8.1 (1.4) 8.0 (2.3)  
Gender     P=0.76 
Male 24 (80.0) 1 (25.0) 8.1 (1.7) 8.0 (1.5)  
Country of birth     P=0.47 
Born in Australia 21 (70.0) 1 (25.0) 8.2 (1.1) 8.0 (2.0)  
Born from overseas 
†
 9 (30.0) 3 (75.0) 8.0 (2.2) 9.0 (3.3)  
English spoken at home 30 (100.0) 3 (75.0) 8.1 (1.6) 9.0 (2.0) P=0.71 
Aboriginal   1 (3.3) 0 N/A N/A P=0.77 
Education and schooling     P=0.25 
Primary school or less 1 (3.3) 0 N/A N/A  
High school-partial completion  8 (26.7) 2 (50.0) 8.3 (1.2) 8.0 (2.3)  
High school (completed) 5 (16.7) 0 8.4 (1.9) 9.0 (2.5)  
TAFE or Trade 8 (26.7) 0 7.8 (1.2) 8.0 (2.3)  
University 8 (26.7) 2 (50.0) 8.4 (2.1) 9.0 (0.8)  
Private health insurance 25 (83.3) 3 (75.0) 8.2 (1.5) 8.5 (1.8) P=0.95 
Assistance required 
†† 
for the completion of the 
HLQ questionnaire  
9 (30.0) 0 7.4 (1.1) 7.0 (2.0) P=0.03 
Lives alone 10 (33.3) 0 8.5 (1.5) 9.0 (2.5) P=0.38 
*     Comparison of warfarin knowledge scores across subgroups using Mann-Whitney test.
 
†     Born in countries including Germany, Taiwan, Philippines, New Zealand, United Kingdom and Malaysia. 
††  Assistance refers to explaining questions, statements and responses to the participant.  
Abbreviations: SD=standard deviation; IQR =Interquartile range; N/A: not applicable; TAFE: Technical And Further Education 
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RESULTS  
Participant characteristics  
Among the study’s 34 participants, 30 were patients taking 
warfarin and 4 were carers of patients taking warfarin 
(Table 1). The median age for patients was 81.0 years, 
80.0% were male, and 30.0% were born overseas. The 
highest level of education attained by the majority of 
patients was: University (26.7%), Technical and Further 
Education or Trade (26.7%) and partial high schooling 
(26.7%). The median age of carers was 61.0 years (range 43 
to 85 years), with three being overseas-born females. Two 
carers completed partial schooling and the other two carers 
were university educated. 
Approximately 94.1% of patients (n=32) had multimorbidity 
(i.e., co-occurrence of 3 or more chronic conditions32) and 
88.2% (n=30) used polypharmacy (i.e.  5 or more 
medications33) (Table 2). Aside from cardiovascular issues, 
the most common chronic medical conditions were: 
respiratory (47.1%) and rheumatological (47.1%) (Table 2). 
The most common number of long-term medications used 
were: antithrombotics (100%) cardiovascular (88.2%) and 
complementary and alternative medicines (CAMS) 
including herbs or vitamins (64.7%) (Table 2). 
The prevailing indication for warfarin was stroke prevention 
in atrial fibrillation (61.8%). Most patients had been taking 
warfarin for between 6 to 10 years (32.4%) and recalled 
Table 2. Patients’ history of warfarin use, medical conditions and medications 
Warfarin use and information provision 









whose warfarin is 
managed by carers (N=4) 
All participants 
(N=34) 
Duration of warfarin use    
 < 1 years 2 (6.7) 0 2 (5.9) 
1 to 5 years 7 (23.3) 3 (75.0) 10 (29.4) 
6 to 10 years 10 (33.3) 1 (25.0) 11 (32.4) 
11 to 15 years 5 (16.7) 0 5 (14.7) 
16 to 20 years 3 (10.0) 0 3 (8.8) 
>20 years 3 (10.0) 0 3 (8.8) 
Indication for warfarin    
Atrial Fibrillation (AF) 19 (63.3) 2 (50.0) 21(61.8) 
Stroke or transient ischaemic attack 2 (6.7) 1 (25.0) 3 (8.8) 
AF and stroke or transient ischaemic attack 2 (6.7) 0 2 (5.9) 
Deep vein thrombosis or Pulmonary Embolism 5 (16.7) 0 5 (14.7) 
Valve replacement 2 (6.7) 1 (25.0) 3 (8.8) 
Chronic medical conditions (≥3) 28 (93.3) 4 (100.0) 32 (94.1) 
Types of medical conditions    
Cardiovascular 30 (100) 4 (100) 34 (100) 
Respiratory 15 (50.0) 1 (25.0) 16 (47.1) 
Rheumatology 13 (43.3) 3 (75.0) 16 (47.1) 
Endocrine 12 (40.0) 2 (50.0) 14 (41.2) 
Other 
‡
 17 (56.7) 4 (100.0)) 21 (61.8) 
Gastrointestinal 13 (43.3) 1 (25.0) 14 (41.2) 
Neurology 8 (26.7) 2 (50.0) 10 (29.4) 
Liver or kidney 8 (26.7) 1 (25.0) 9 (26.5) 
Psychotropic 4 (13.3) 4 (100.0) 8 (23.5) 
Cancer 5 (16.7) 2 (50.0) 7 (20.6) 
Stroke or transient ischaemic attack 4 (13.3) 1 (25.0) 5 (14.7) 
Polypharmacy (5 or more long term medications) 26 (86.7) 4 (100) 30 (88.2) 
Number of patients taking long term medications in 
the following categories ‡ ‡ 
   
Antithrombotic 30 4 (100) 34 (100) 
Cardiovascular 26 4 (100) 30 (88.2) 
Herbs/vitamins 18 4 (100) 22 (64.7) 
Gastrointestinal 15 4 (100) 19 (55.9) 
Analgesics 13 1 (25) 14 (41.2) 
Dermatological 12 1 (25) 13 (38.2) 
Respiratory 12 0 12 (35.3) 
Psychotropic 9 3 (75) 12 (35.3) 
Endocrine 8 2 (50) 10 (29.4) 
Rheumatology 8 0 8 (23.5) 
Genitourinary 8 0 8 (23.5) 
Ophthalmic 6 1 (25) 7 (20.6) 
Neurological 4 1 (25) 5 (14.7) 
Antimicrobial 3 0 3 (8.8) 
Other‡‡‡  11 1 (25) 12 (35.3) 
‡
  
Other conditions include; ophthalmology, dermatology, ear, genitourinary, peripheral neuropathy, restless legs syndrome,obesity, bone 
marrow disorder and shingles. 
‡‡    Patient’s records may have reported more than one long term medication. 
‡‡‡  Other long term medications include; ear ointment, antifungal, iron chelator, non-cytotoxic antineoplastic, intranasal corticosteroid 
spray and somatostatin analogue. 
‡‡‡‡  Primary care settings include; General Practice Medical Centre, Community Pharmacy and Specialist’s office.  
Abbreviations: AF = atrial fibrillation; NA= Not Applicable. 
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receiving warfarin education from their general practitioner 
or specialist doctor (76.5%). The location of their warfarin 
education was most commonly a primary care setting 
(44.1%). The time since the participant last recalled 
receiving information about warfarin was 1 to 5 years 
(35.3%) for most patients. One carer reported never 
receiving any formal warfarin education. 
Assessment of Warfarin Knowledge  
Across the 34 participants, the mean warfarin score out of 
10 was 8.3, indicating a good level of knowledge about the 
basic aspects of warfarin use.  The questions that received 
the highest proportion of correct responses (Figure 1) 
were: 
• question 1 (97.1%): “Reason for taking warfarin” 
• question 8 (97.1%): “Informing other health care 
providers”  
• question 3 (88.2%): “What to do if you miss a dose of 
warfarin”  
The questions that received the lowest proportion of 
correct responses were: 
• question 6: “The importance of a consistent diet” (58.8%) 
• question 10: “When to seek urgent medical attention” 
(67.6%) and  
• question 5: “What happens if an INR value is below the 
target INR range” (73.5%) 
The mean warfarin knowledge score was the same for face-
to-face and telephone interviews. 
Assessment of Health Literacy 
Table 3 summarises the median scores for each HLQ scale. 
The strengths and limitations for the sample population can 
be explained in terms of the number of participants with a 
lower or higher level of health literacy for each scale. The 
scale with the largest number of participants 
demonstrating a lower level of health literacy (N=17) was 
scale 5 (“Appraisal of health information”), i.e., many more 
participants indicated that they did not consistently 
appraise the quality and reliability of health information.  
The scales with the most participants with a higher level of 
literacy was scale 1 (“Feeling understood and supported by 
healthcare providers”) (N=32) and scale 6 (“Ability to 
actively engage with healthcare providers”) (N=30).  
There were no significant differences between the 
participants’ warfarin knowledge scores and gender, 
country of birth, Aboriginal or Torres Strait Islander status, 
whether English spoken at home, number of chronic 
medical conditions, number of long-term medications, age, 
private health insurance status, duration of warfarin 
therapy, and the time since they last were educated about 
warfarin.  
Patients who needed assistance in completing the HLQ had 
significantly lower warfarin knowledge scores compared to 
those patients who did not need assistance (p=0.03). 
Participants born overseas had significantly lower HLQ 
scores for scale 1 (Feeling understood and supported by 
healthcare providers) compared to those born in Australia 
(p=0.01). Participants who took 5 or more long-term 
medications had lower HLQ scores for scale 9, (Understand 
health information enough to know what to do) compared 
to those who took less than 5 medications (p=0.04). There 
Table 2. (cont.)  Patients’ history of warfarin use, medical conditions and medications 
Warfarin use and Information provision 
Number of participants 









whose warfarin is 
managed by carers (N=4) 
All participants 
(N=34) 
Time since information about warfarin was last received 
0 to 1 years 4 (13.3) 0 4 (11.8) 
1 to 5 years 9 (30) 3 (75.0) 12 (35.3) 
6 to 10 years 9 (30) 0 9 (26.5) 
11 to 15 years 2 (6.7) 0 2 (5.9) 
16 to 20 years 2 (6.7) 0 2 (5.9) 
>20 years 3 (10.0) 0 3 (8.8) 
Not sure  1 (3.3) 1 (25.0) 2 (5.9) 
Main provider or warfarin education / information when warfarin was initiated 
General Practitioner/Specialist 23 (76.7) 3 (75) 26 (76.5) 
Pharmacist 2 (6.7) 0 2 (5.9) 
General Practitioner/Specialist and Nurse 4 (13.3) 0 4 (11.8) 
Not sure  1 (3.3) 0 1 (2.9) 
No one 0 1 (25) 1 (2.9) 
Location of education:    
Primary care setting
‡‡‡‡ 
15 (50.0) 0 15 (44.1) 
Hospital setting 12 (40.0) 2 (50) 14 (41.2) 
Primary care and hospital settings 3 (10.0) 0 3 (8.8) 
Not sure 0 1 (25) 1 (2.9) 
Patient self-reported nil counselling received 0 1 (25) 1 (2.9) 
‡
  
Other conditions include; ophthalmology, dermatology, ear, genitourinary, peripheral neuropathy, restless legs syndrome,obesity, 
bone marrow disorder and shingles. 
‡‡  Patient’s records may have reported more than one long term medication. 
‡‡‡  Other long term medications include; ear ointment, antifungal, iron chelator, non-cytotoxic antineoplastic, intranasal  corticosteroid 
spray and somatostatin analogue. 
‡‡‡‡  Primary care settings include; General Practice Medical Centre, Community Pharmacy and Specialist’s office. 
Abbreviations: AF = atrial fibrillation; NA= Not Applicable. 
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was no significant association between other 
characteristics, warfarin knowledge scores and HLQ scores. 
 
DISCUSSION 
This study has described the level of warfarin knowledge 
and assessed the health literacy amongst an older 
population taking warfarin and a few carers in the local 
Australian primary care setting.  
The majority of participants in our study had several 
characteristics that highlight why the management of this 
older population can be complex. Older age has been 
associated with a lack of warfarin knowledge, low literacy16 
comorbidities34, polypharmacy and drug interactions.35 
Polypharmacy has been also associated with increased 
mortality, stroke and major bleeding for patients with atrial 
fibrillation.35 Consequently, the need for carer assistance in 
the management of warfarin for older patients may be 
required.  
The gaps in warfarin knowledge encountered in this study 
primarily related to medication safety issues and self-
management strategies with respect to a consistent diet, 
recognising when to seek medical attention and actions to 
Table 3. Health Literacy Questionnaire (HLQ) scores for all participants (N=34) 
 
Median score (IQR)  
for all participants  
Number of participants 






Range 1 (lowest score) -   
4 (highest score) 
§§  
1. Feeling understood and supported by healthcare providers (N= 4 items) 3.5 (0.8) 2 (5.9%) 
2. Having sufficient information to manage my health (N= 4 items) 3.0 (0.3) 7 (20.6 %) 
3. Actively managing my health  (N= 5 items) 3.0 (0.7) 12 (35.3%) 
4. Social support for health  (N= 5 items) 3.1 (0.7) 8 (23.5%) 
5. Appraisal of health information  (N= 5 items) 2.9 (0.7) 17 (50.0%) 
 
Range 1 (lowest score) -     
5 (highest score) 
§§§  
6. Ability to actively engage with healthcare professionals  (N= 5 items) 4.2 (0.6) 4 (11.8) 
7. Navigating the healthcare system (N= 6 items) 4.1 (0.5) 7 (20.6) 
8. Ability to find good health information (N= 5 items) 4.0 (0.5) 12 (35.3) 
9. Understand health information enough to know what to do (N= 5 items) 4.1 (0.8) 10 (29.4) 
§  Lower level of health literacy was defined as a mean scale score of less than 3 for scales 1 to 5 and a mean scale score of less than 4 
for scales 6 to 9. 
§ §  Mean Scale scores range between 1 and 4 for the first 5 scales. Items asked from how strongly the participant disagrees (lowest score 
of 1) to strongly agrees (highest score of 4).  
§ § § Mean Scale scores range between 1 and 5 for scales 6 to 9. Items asked how difficult or easy the following tasks are for you now from 
cannot do (lowest score of 1) to very easy (highest score of 5). 
Abbreviations: HLQ, Health Literacy Questionnaire; IQR, interquartile range. 
Figure 1. Proportion of participants correctly answering specific questions on Warfarin Knowledge Questionnaire  
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take when the international normalised ratio (INR) readings 
are outside the desired target range.  
A particularly significant finding here is the gap in 
knowledge regarding knowing when to seek help; in the 
context of high-risk anticoagulant therapy, patients and 
their carers must be acutely aware of  the signs and 
symptoms of potentially life-threatening adverse effects 
from warfarin (e.g., haemorrhage) which require urgent 
medical attention. Increasing patient’s knowledge about 
these will help to reduce their risk of major complications 
and poor treatment outcomes (including death).36,37 These 
findings are similar to those reported by other studies in 
the literature, and highlight ongoing problems with respect 
to patient’s understanding of these key points.9,38 In 
addition to gaps in warfarin knowledge, the majority of our 
study participants had not received updated warfarin 
counselling in more than 1 to 5 years. These results 
highlight a need for effective and ongoing education with 
regular follow-up to address the knowledge gaps. 
To overcome these knowledge gaps warfarin patient 
education needs to be standardised39 and more targeted to 
topics relating to patient safety and actions required. In this 
study, most participants were educated by their general 
practitioners or physicians in the primary care setting, at 
the time of warfarin commencement. In our study, despite 
being long-term users of warfarin, the majority of 
participants had not had a warfarin ‘refresher’ in the 
previous one to five year period, nor had they received 
warfarin education by pharmacists. This is important as 
knowledge retention on some aspects of warfarin is as 
short as 28 to 56 days.40 General practitioners or specialists 
may not have sufficient time to educate and follow-up on 
the patients about warfarin.25 To address this barrier, a 
multidisciplinary approach, involving doctors,  pharmacists, 
nurses and nutritionists36, is suggested to facilitate  patient 
follow-up and re-education. The beneficial role of 
pharmacists in supporting patients receiving anticoagulants 
in the hospital, community and general practice settings, 
has been particularly highlighted in the literature.40-42  
In considering approaches to patient education (Table 4), it 
is important to note that around half of the study 
participants had a lower level of health literacy for scale 5 
(“Appraisal of information”). These participants could not 
understand most health information and could become 
confused when there is conflicting information.19 A unique 
finding was that patients who needed assistance in 
completing the health literacy questionnaire had 
significantly lower warfarin knowledge scores, suggesting 
they may also need specific assistance with understanding 
information about warfarin. Health care providers may 
need to communicate information about warfarin in 
appropriate formats so that these patients can understand 
the key messages and improve their knowledge. Although 
the literature identifies that health literacy must be 
assessed and addressed for effective patient education, 
there is limited research specifically reporting on successful 
interventions in the context of anticoagulation 
management. More broadly, one method of educating 
patients with limited health literacy includes pharmacist 
counselling about warfarin supported by a written 
information booklet.40 In addition, the literature has 
suggested specific communication techniques to support 
patients with limited health literacy in understanding their 
medications, including: the Indian Health Service model 
(i.e., 3 key questions are asked to assess a patient’s 
baseline knowledge: What were you told this medication is 
for?, How were you told to use it?, and What were you told 
to expect?)43,44; ‘Teach-back’45; ‘Ask-tell-ask’ methods to 
confirm understanding30; “Ask Me 3” method (i.e., patients 
ask themselves: 1) What is my main problem?, 2) What do I 
need to do?, and 3) Why is it important for me to do 
this?)46;  or use of a digitised colour menus of warfarin 
tablets to confirm regimen dosage concordance.47 Other 
techniques include using slow speech, limiting the number 
of key points discussed to three or less48, reinforcing 
messages using pictures or  graphs48, using plain language, 
assessing health information, and involving consumers in 
the process of developing information through focus 
groups, online surveys and telephone interviews, and using 
shared-decision making tools to communicate risk 
information about treatment options.30 Regardless of the 
techniques that may be used, there is a need to implement 
specific policies in practice to guide the assessment of 
health literacy in patients and ensure it is appropriately 
addressed. In our local setting, these study findings have 
prompted the development of a warfarin action plan 
(written information leaflet) that considers the principles 
espoused in many of the communication techniques listed 
above. This warfarin action plan will be subsequently 
evaluated as a resource in the education of patients with 
limited health literacy, particularly older persons and their 
carers.  
Other notable study findings included the lower level of 
health literacy identified in participants who were born 
overseas or who took five or more long-term medications. 
In our study, participants who were born overseas found it 
difficult to feel understood and supported by healthcare 
providers. Participants who took 5 or more long-term 
medications had difficulty in understanding health 
information to enable them to know what actions to take. 
Previous studies have reported similar findings15, including 
Table 4. Recommended Communication Strategies for healthcare providers to use when caring for people with lower health literacy 
 Prioritise the educational domains, standardise the educational content and deliver the content efficiently.
39
  
 For leaflets use simple, clear statements in lay terminology that are easy to follow. Use simple and familiar icons and simple list 
formatting. Ensure patients are able to find information and take the appropriate actions.
57
  
 Work with consumers for the development of simple and clear drug information.
57
 
 Supplement written information with other modes of delivery such as verbal information, multidisciplinary programs involving 
doctors, nurses, dieticians and pharmacists, DVD, booklets, audiovisual resources depicting real-life scenarios, brown bag medication 
reviews, and visual aids.
58
 
 Involve the carer and family members when doing patient education to older patients.
9,38
 
 Use the teach back method for patients with low literacy to confirm comprehension.
58
  
 Help patients to ask questions. For example, ask, “What are your questions?”.
58
  
 Help patients make decisions about their care. Communicate risks and benefits of information in a balanced and transparent way.
59
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that patients using polypharmacy and who have 
inadequate health literacy also have low understanding of 
pre-admission medications such as the frequency and 
dosing of their medications.49 Polypharmacy has been 
associated with increased mortality, stroke and major 
bleeding for patients with atrial fibrillation.35 Consequently, 
vulnerable patients who are at risk of poor medication 
understanding (due to factors such as polypharmacy and 
low literacy) may need more intensive medication 
reconciliation, educational counselling and follow-up to 
prevent post-discharge adverse drug events.49  
Culturally and linguistically diverse (CALD) patients may not 
be able to fully engage with doctors and other healthcare 
providers about anticoagulant therapy due to language 
barriers and cultural beliefs.50,51 To address this, education 
about warfarin may need to involve the patient’s family, 
friends or carers, accredited interpreters and/or a health 
care provider that can speak the same language. Further 
research is required to evaluate the use and impact of 
medical interpreters on improving knowledge in CALD 
patients. 
To date, there has been limited research focusing on 
supporting older patients taking oral anticoagulants 
through the use of carers. For this reason, we included a 
small number of carers in our study. The role of the carer in 
shared decision-making has been noted in a previous 
qualitative study.52 However, whilst we know the 
challenges around managing older patients, we also need 
to consider the challenges of supporting the carers of older 
persons, who are often older persons themselves (e.g., 
spouses, partners, adult children). In our study, the mean 
age of carers was 61 years; this signals a need to assess the 
warfarin knowledge and health literacy of carers as well as 
the patients themselves.  
Whilst this study provides insights into the medication 
management challenges of high-risk patients in the local 
setting, this study has several limitations. First, the 
generalisability of the findings may be limited by: the 
relatively small sample size as this was a pilot study, the 
number of general practitioners agreeing to recruit 
patients, the number of participants agreeing to do the 
study, and by the specific characteristics of our study 
sample, i.e., 27% were university-educated with a median 
age of 80, were not culturally diverse nor warfarin-naïve, 
which may have influenced the level of warfarin 
knowledge. Furthermore, our patients were recruited from 
one specific setting (one medical centre). 
The patients in this study may not represent the 
preferences and perspectives of the thousands of patients 
encountered in other practice settings, whether in Australia 
or more globally. Second, the medical staff was involved in 
identifying potential participants so this may have 
introduced some selection bias. Third, having the 
participants answer the questionnaire via the telephone 
may have adversely influenced their experience, compared 
to those who answered in person. Fourth, the shortened 
questionnaire was not specifically validated for use in this 
setting. Fifth, due to the small sample size, the data from 
both patients and carer was combined and precludes an 
exploration of whether any patient characteristics may 
have affected patient preferences. Nevertheless, the study 
provides some useful insights into the local Australian 
practice setting, identifying gaps that need to be filled.  
Future research should focus on involving a greater number 
of participants and their carers from different cultural 
backgrounds, using the multi-dimensional HLQ tool to 
assess health literacy and a validated questionnaire to 
assess knowledge about oral anticoagulants (warfarin and 
the DOACs) in the community and hospital settings. In 
addition, health outcomes of health literacy, knowledge 
and health impact of self-managed patients versus carer-
managed patients taking oral anticoagulants could be 
explored. Furthermore, although there have been some 
studies involving pharmacist education to older 
persons40,42,53 and those with limited literacy40, there is a 
need for pharmacists to develop interventions to support 
CALD patients about warfarin. Several studies in the 
literature have highlighted the need for medicines 
information among CALD patients.54-56 Pharmacists have an 
important role in addressing this need for medicines 
information as they are easily accessible and are 
conveniently located in several health care settings (i.e. 
hospital, community and home). 
 
CONCLUSIONS 
This study provides insights regarding the challenges of 
managing warfarin in older persons due to their 
characteristics, and highlights the ongoing knowledge gaps 
about warfarin, the limitations of health literacy, and the 
importance of involving carers of the older persons during 
education. Participants born overseas and those using 
polypharmacy may require more support with tailored 
education and follow-up to improve their health literacy 
and warfarin knowledge. 
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